CD4 and melanoma: Flow cytometry analysis confirmed significantly higher percentages of PD-1-expressing CD4 and CD8 T cells in melanoma tumors from mice exposed to the combo DAC/IL-33 treatment, but not from those receiving single treatments, with respect to untreated animals (Fig. 2G).